当前支持胆管癌遗传基础的挑战。
Current challenges to underpinning the genetic basis for cholangiocarcinoma.
机构信息
Department of Medical, Surgery and Experimental Sciences, Division of Experimental Pathology and Oncology, University of Sassari, Sassari Italy.
Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
出版信息
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):511-526. doi: 10.1080/17474124.2021.1915128. Epub 2021 Apr 23.
Abstract
AREAS COVERED
This review provides an overview regarding the current scenario and knowledge of the CCA genomic landscape and the potentially actionable molecular aberrations in each CCA subtype.
EXPERT OPINION
The establishment and advances of high-throughput methodologies applied to genetic and epigenetic profiling are changing many cancer types' therapeutic landscape , including CCA.The large body of data generated must be interpreted appropriately and eventually implemented in clinical practice. The following advancements toward precision medicine in CCA management will require designing better clinical trials with improved methods to stratify biliary tumor patients.
摘要
涵盖领域
本文综述了当前关于 CCA 基因组图谱的知识和现状，以及每种 CCA 亚型中潜在可靶向的分子异常。
专家意见
应用于遗传和表观遗传分析的高通量方法的建立和进展正在改变许多癌症类型的治疗格局，包括 CCA。必须适当地解释大量生成的数据，并最终将其应用于临床实践。以下是在 CCA 管理方面迈向精准医学的进展，这需要设计更好的临床试验，并改进分层胆管肿瘤患者的方法。
相似文献
1
Current challenges to underpinning the genetic basis for cholangiocarcinoma.当前支持胆管癌遗传基础的挑战。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):511-526. doi: 10.1080/17474124.2021.1915128. Epub 2021 Apr 23.
2
Intrahepatic cholangiocarcinoma: current management and emerging therapies.肝内胆管癌：当前的治疗与新兴疗法
Expert Rev Gastroenterol Hepatol. 2017 May;11(5):439-449. doi: 10.1080/17474124.2017.1309290. Epub 2017 Mar 29.
3
Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.整合分析揭示了在胆管内乳头状和管状乳头状胆管癌发生过程中早期且独特的遗传和表观遗传变化。
Gut. 2022 Feb;71(2):391-401. doi: 10.1136/gutjnl-2020-322983. Epub 2021 Jan 19.
4
Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.胆管癌最新进展：基因组研究对临床管理的潜在影响
Z Gastroenterol. 2017 Jun;55(6):575-581. doi: 10.1055/s-0043-102581. Epub 2017 Apr 4.
5
Targeting cholangiocarcinoma.胆管癌靶向治疗。
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1454-1460. doi: 10.1016/j.bbadis.2017.08.027. Epub 2017 Aug 24.
6
Practical considerations for pathological diagnosis and molecular profiling of cholangiocarcinoma: an expert review for best practices.胆管癌病理诊断和分子谱分析的实用考虑：最佳实践的专家综述。
Expert Rev Mol Diagn. 2024 May;24(5):393-408. doi: 10.1080/14737159.2024.2353696. Epub 2024 May 16.
7
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).专家共识文件：胆管癌：来自欧洲胆管癌研究网络（ENS-CCA）的当前知识和未来展望共识声明。
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51. Epub 2016 Apr 20.
8
Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.中国和西方的肝内胆管癌患者的临床显著基因组改变。
BMC Cancer. 2021 Feb 12;21(1):152. doi: 10.1186/s12885-021-07792-x.
9
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.靶向测序在晚期胆道癌患者管理中的治疗相关性：DNA 损伤修复基因突变作为预测生物标志物。
Eur J Cancer. 2019 Oct;120:31-39. doi: 10.1016/j.ejca.2019.07.022. Epub 2019 Aug 30.
10
Cholangiocarcinoma: new perspectives for new horizons.胆管癌：新视角，新视野。
Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1367-1383. doi: 10.1080/17474124.2021.1991313. Epub 2021 Nov 9.
引用本文的文献
1
Role of interleukins in the pathogenesis of cholangiocarcinoma: A literature review.白细胞介素在胆管癌发病机制中的作用：文献综述。
World J Gastrointest Oncol. 2025 Jul 15;17(7):107341. doi: 10.4251/wjgo.v17.i7.107341.
2
Apigenin Induces Apoptosis and Inhibits Migration in Human Cholangiocarcinoma Cells.芹菜素诱导人胆管癌细胞凋亡并抑制其迁移。
Toxics. 2025 Jan 30;13(2):112. doi: 10.3390/toxics13020112.
3
Distinct cholangiocarcinoma cell migration in 2D monolayer and 3D spheroid culture based on galectin-3 expression and localization.基于半乳糖凝集素-3表达和定位的二维单层和三维球体培养中不同胆管癌细胞的迁移
Front Oncol. 2023 Jan 12;12:999158. doi: 10.3389/fonc.2022.999158. eCollection 2022.
4
Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?胆管癌：最有价值的治疗靶点是什么——癌相关成纤维细胞、免疫细胞，还是 T 细胞以外的细胞？
Expert Opin Ther Targets. 2021 Oct;25(10):835-845. doi: 10.1080/14728222.2021.2010046. Epub 2021 Dec 3.
本文引用的文献
1
Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.整合分析揭示了在胆管内乳头状和管状乳头状胆管癌发生过程中早期且独特的遗传和表观遗传变化。
Gut. 2022 Feb;71(2):391-401. doi: 10.1136/gutjnl-2020-322983. Epub 2021 Jan 19.
2
Intraductal Papillary Neoplasm of Bile Duct: Updated Clinicopathological Characteristics and Molecular and Genetic Alterations.胆管内乳头状肿瘤：更新的临床病理特征及分子和基因改变
J Clin Med. 2020 Dec 9;9(12):3991. doi: 10.3390/jcm9123991.
3
Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.肝细胞癌-胆管细胞癌混合癌的临床病理特征及复发模式。
World J Surg Oncol. 2020 Dec 4;18(1):319. doi: 10.1186/s12957-020-02099-w.
4
Genomic profiling of multifocal intrahepatic cholangiocarcinoma reveals intraindividual concordance of genetic alterations.多灶性肝内胆管癌的基因组分析揭示了个体内遗传改变的一致性。
Carcinogenesis. 2021 Apr 17;42(3):436-441. doi: 10.1093/carcin/bgaa124.
5
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting.胆管癌中的异柠檬酸脱氢酶（IDH）信号通路：从生物学原理到治疗靶点
Cancers (Basel). 2020 Nov 9;12(11):3310. doi: 10.3390/cancers12113310.
6
A unified model for the G1/S cell cycle transition.G1/S细胞周期转换的统一模型。
Nucleic Acids Res. 2020 Dec 16;48(22):12483-12501. doi: 10.1093/nar/gkaa1002.
7
Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?现有的原发性肝癌分期系统是否适用于肝细胞癌-肝内胆管癌？
Hepatobiliary Pancreat Dis Int. 2021 Feb;20(1):13-20. doi: 10.1016/j.hbpd.2020.10.002. Epub 2020 Oct 27.
8
Cholangiocarcinoma miscoding in hepatobiliary centres.肝胆中心胆管癌错配。
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
9
Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.具有 IDH1/2 突变相关选择性基因甲基化的肝内胆管癌及其临床病理特征。
Sci Rep. 2020 Sep 25;10(1):15820. doi: 10.1038/s41598-020-72810-0.
10
Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.富替替尼是一种新型不可逆 FGFR1-4 抑制剂，对 FGFR 失调肿瘤具有选择性抗肿瘤活性。
Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24.
Zotero 插件